据了解，翼帆医药是水滴公司旗下的数字化临床患者招募平台，依托水滴公司庞大的患者群体和数字化 AI能力开展患者招募等业务，聚焦解决临床试验"招募慢、匹配难"的行业痛点，并助力国内外知名药企 提高研发效率。 近日，水滴公司旗下北京翼帆风顺医药科技有限公司自主研发的 "临床药物试验患者智能匹配技术" 正 式获得国家发明专利（专利号：ZL202210080502.4）：临床药物试验患者的匹配方法、装置及计算机设 备。水滴公司此前已经自主研发水滴水守大模型，驱动业务全面提效。此次新的专利技术通过深度神经 网络与自然语言处理技术的创新融合，彻底解决了传统临床药物试验患者招募中 "工作量大、效率低 下、易出错" 的行业痛点，为医药创新研发按下 "加速键"。 财经频道更多独家策划、专家专栏，免费查阅>> 水滴公司是行业内最早布局AI大模型应用的公司之一，每年投入近3亿元用于研发，目前已经积累了 100多项人工智能技术专利。水滴公司此前自主研发的水滴水守大模型，已经成为驱动业务提效的 "中 枢神经"，广泛应用于产品创新、用户服务等众多业务场景，全面提升保险及健康服务全流程的效率和 质量。 责任编辑：钟离 此次推出的智能匹配技术 ...

Core Viewpoint - Waterdrop Group's subsidiary, Beijing Yifan Fengshun Pharmaceutical Technology Co., Ltd., has developed a patented "Intelligent Patient Matching Technology" for clinical drug trials, addressing inefficiencies in patient recruitment [1][2]. Group 1: Technology Overview - The newly patented technology utilizes a dual-track approach of "numerical matching + semantic embedding matching" to achieve precise patient-trial project matching [2]. - The system disaggregates patient information into numerical data (e.g., age, lab results) and clinical history, while also breaking down trial inclusion/exclusion criteria into corresponding numerical and descriptive information [2]. - The technology boasts three core advantages: a 300% increase in recruitment efficiency, over 92% accuracy in matching, and strong adaptability to various data formats and trial criteria [2]. Group 2: Industry Impact - The application of this technology is expected to save pharmaceutical companies significant time and labor costs in patient recruitment, while also connecting eligible patients with high-quality clinical trial resources [3]. - The technology has been piloted in multiple top-tier hospitals and pharmaceutical companies, successfully matching nearly 1,000 patients and helping clinical trial projects meet recruitment goals 3-6 months ahead of schedule [3]. - Yifan Pharmaceutical focuses on addressing the industry pain points of slow recruitment and difficult matching, leveraging Waterdrop's extensive patient base and digital capabilities to enhance research efficiency for renowned pharmaceutical companies [3].